108 related articles for article (PubMed ID: 35868534)
21. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.
Liao X; Zhang L; Thrasher JB; Du J; Li B
Mol Cancer Ther; 2003 Nov; 2(11):1215-22. PubMed ID: 14617795
[TBL] [Abstract][Full Text] [Related]
22. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
Chen L; Song Y; Hou T; Li X; Cheng L; Li Y; Xing Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):194. PubMed ID: 35659274
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of endogenous regulation of the type I interferon response by suppressor of IκB kinase epsilon (SIKE), a novel substrate of TANK-binding kinase 1 (TBK1).
Marion JD; Roberts CF; Call RJ; Forbes JL; Nelson KT; Bell JE; Bell JK
J Biol Chem; 2013 Jun; 288(25):18612-23. PubMed ID: 23649622
[TBL] [Abstract][Full Text] [Related]
24. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
26. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Hishida S; Kawakami K; Fujita Y; Kato T; Takai M; Iinuma K; Nakane K; Tsuchiya T; Koie T; Miura Y; Ito M; Mizutani K
Prostate; 2021 Jun; 81(9):592-602. PubMed ID: 33905554
[TBL] [Abstract][Full Text] [Related]
27. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
28. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
[TBL] [Abstract][Full Text] [Related]
29. EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling.
Jiang X; Guo S; Wang S; Zhang Y; Chen H; Wang Y; Liu R; Niu Y; Xu Y
Cancer Res; 2022 Mar; 82(5):831-845. PubMed ID: 34965937
[TBL] [Abstract][Full Text] [Related]
30. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
[TBL] [Abstract][Full Text] [Related]
31. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
32. Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells.
Schnepp PM; Shelley G; Dai J; Wakim N; Jiang H; Mizokami A; Keller ET
Mol Cancer Res; 2020 Sep; 18(9):1290-1301. PubMed ID: 32513898
[TBL] [Abstract][Full Text] [Related]
33. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization.
Li Y; Zhang B; Xiang L; Xia S; Kucuk O; Deng X; Boise LH; Dong JT
Theranostics; 2020; 10(17):7656-7670. PubMed ID: 32685011
[TBL] [Abstract][Full Text] [Related]
34. TRIM11 negatively regulates IFNβ production and antiviral activity by targeting TBK1.
Lee Y; Song B; Park C; Kwon KS
PLoS One; 2013; 8(5):e63255. PubMed ID: 23675467
[TBL] [Abstract][Full Text] [Related]
35. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
[TBL] [Abstract][Full Text] [Related]
36. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis.
Zhong W; Wu K; Long Z; Zhou X; Zhong C; Wang S; Lai H; Guo Y; Lv D; Lu J; Mao X
Microbiome; 2022 Jun; 10(1):94. PubMed ID: 35710492
[TBL] [Abstract][Full Text] [Related]
37. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
[TBL] [Abstract][Full Text] [Related]
38. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
39. [Update of combined therapies with docetaxel for hormone-independent prostate cancer].
Li TQ; Wang JS
Zhonghua Nan Ke Xue; 2008 Mar; 14(3):264-7. PubMed ID: 18488345
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory molecules facilitate the development of docetaxel-resistant prostate cancer cells in vitro and in vivo.
Wang S; Han L; Li J; Liu Y; Wang S
Fundam Clin Pharmacol; 2022 Oct; 36(5):837-849. PubMed ID: 35255161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
